OMNISCAN 287 MG
GADODIAMIDE : 287 MG · DIN 02172771 · GE HEALTHCARE CANADA INC
Health Canada status: MARKETED
What is OMNISCAN?
OMNISCAN 287 MG contains GADODIAMIDE : 287 MG. It is listed in the Health Canada Drug Product Database under DIN 02172771, held by GE HEALTHCARE CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Oct-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OMNISCAN used for?
Contrast enhancement for MRI of CNS lesions (adults/pediatrics); MRI of thoracic, abdominal, pelvic, breast, retroperitoneal, and musculoskeletal lesions (adults); MRA of renal/aorto-iliac arteries.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02172771 |
|---|---|
| Brand name | OMNISCAN |
| Generic / active ingredient | GADODIAMIDE : 287 MG |
| Manufacturer | GE HEALTHCARE CANADA INC |
| Strength | 287 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | V08CA03 GADODIAMIDE |
| AHFS class | 36:89.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Oct-2006 |
| Original market date | 1997-03-25 00:00:00 |
How is it administered?
CNS: 0.1 mmol/kg (0.2 mL/kg). Body: 0.3 mmol/kg (0.6 mL/kg). MRA: 0.1 mmol/kg (0.2 mL/kg). Administer as bolus IV injection. Use lowest effective dose. Flush with 5 mL saline.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (Section 11 mentioned in TOC but text cuts off). Standard practice: Draw into syringe and use immediately.
How is it supplied?
10 mL vial, 15 mL fill in 20 mL vial, and 20 mL vial; all in boxes of 10.
Contraindications
Chronic severe renal insufficiency (GFR <30 mL/min/1.73m2); acute kidney injury; neonates up to 4 weeks of age; hypersensitivity to gadodiamide or any ingredient in the formulation.
Warnings and precautions
NOT FOR INTRATHECAL USE (fatal reactions). Risk of Nephrogenic Systemic Fibrosis (NSF). Gadolinium accumulation in brain. Risk of anaphylactoid/hypersensitivity reactions.
What can be used instead?
Other Canadian products sharing ATC code V08CA03 GADODIAMIDE. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OMNISCAN LIQ IV 287MG/ML | 287 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02093197 |
Who else supplies GADODIAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GADODIAMIDE appears in 15 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.